| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | Manufacturing method of uncooked food and uncooked food manufactured thereby | US10496604 | 2002-12-20 | US20050003045A1 | 2005-01-06 | Hee-Kyong Bae; Yoon-Hee Whang; Jin-Hee Lee; Jae-kag Lim |
| The present invention related to a manufacturing method of uncooked food and uncooked food manufactured thereby with improved taste and conservation period not by heating but using lactic ferments that can eradicate microorganism existing in grain, fruit and vegetables, and the method for preparing uncooked food that comprises the steps of pre-treating foods made of grain, fruit or vegetables by uncooked method; and incubating said pre-treated food by mixing with solution containing method activated lactic ferments at 15˜35° C. for 0.25˜8 hours and additionally further includes the step of activating lactic ferments in the solution containing sugar such as lactose; and adding sugar such as glucose or fructose into the mixture of the processed food and the solution containing the lactic ferments during the incubating step. | ||||||
| 142 | 비만 및 비만 관련 질환을 치료하기 위한 프로바이오틱 조성물 및 방법 | KR1020157010157 | 2013-08-12 | KR1020150118084A | 2015-10-21 | 올름스테드,스티픈,프랜시스 |
| 본발명은그를필요로하는포유동물에서비만, 당뇨및 관련질환들의증상및 징후를경감또는저감시키기위한그리고그 치료를위한방법및 조성물을제공하는데, 상기방법은비만, 당뇨또는심혈관질병의징후또는증상한 가지이상을경감, 저감또는치료하는데충분한시간동안, 별개이지만보완적인탄수화물대사경로들을갖는프로바이오틱미생물들의혼합물을포함하는약학적으로허용되는조성물의유효량을투여하는것을포함한다. 약학적및 영양상제제에사용하기위한목적하는특성을갖는조성물, 및방법이제공된다. | ||||||
| 143 | 사워도우의 제조에서 6 개 이상의 젖산균 및/또는비피더스균 종들의 혼합물 | KR1020077021205 | 2006-03-07 | KR101315393B1 | 2013-10-07 | 데시모네,클라우디오; 피로바노,프랑코 |
| 베이커리 및 의료 분야에 사용하기 위한 6 개 이상의 젖산균 및 비피더스균 종들의 혼합물을 개시한다. 상기 바람직한 혼합물은 스트렙토코커스 써모필루스, 비피도박테리움 인판티스, 비피도박테리움 롱검, 비피도박테리움 브레베, 락토바실러스 액시도필루스, 락토바실러스 플란타룸, 락토바실러스 카제이, 락토바실러스 델브루엑키 서브스페시즈 불가리쿠스를 포함한다. 상기 혼합물은 사워도우, 발효 조성물에 유용하다. 상기로부터 수득된 베이커리류 및 다른 식품들을 개시한다. 이러한 상품들은 글루텐 함량이 낮거나 없으며 소아 지방변증을 앓고 있는 환자의 식사에 혼입하거나, 밀가루 알부민 및 글로불린으로 인한 알러지의 위험성을 감소시키거나, 정신분열성 증상을 치료하거나, 장 식이요법용 제품의 제조에 적합하다. 젖산균, 비피더스균, 사워도우, 발효, 베이커리 | ||||||
| 144 | 비열처리 생식품의 제조방법 및 그로부터 수득되는 생식품 | KR1020010081351 | 2001-12-19 | KR100436038B1 | 2004-06-12 | 배희경; 황윤희; 이진희; 임재각 |
| The present invention related to a manufacturing method of uncooked food and uncooked food manufactured thereby with improved taste and conservation period not by heating but using lactic ferments that can eradicate microorganism existing in grain, fruit and vegetables, and the method for preparing uncooked food that comprises the steps of pre-treating foods made of grain, fruit or vegetables by uncooked method; and incubating said pre-treated food by mixing with solution containing method activated lactic ferments at 15~35° C. for 0.25~8 hours and additionally further includes the step of activating lactic ferments in the solution containing sugar such as lactose; and adding sugar such as glucose or fructose into the mixture of the processed food and the solution containing the lactic ferments during the incubating step. | ||||||
| 145 | 프로바이오틱스 조합물 | KR1020037009902 | 2002-01-17 | KR1020040012717A | 2004-02-11 | 매이래-매키넨안니카; 주오말라이넨타르자; 바랄라오우티 |
| 본 발명은 유산균(lactobacilli), 프로피온산 박테리아(propionic acid bacteria) 및/또는 비피도박테리아(bifidobacteria)의 서로 다른 조합을 포함하는 프로바이오틱스 조합물에 관한 것이다. 상기 조합물을 적합한 프리바이오틱스와 혼합하여 신바이오틱스를 생성하는 것이 바람직하다. 본 발명의 조합물은 그 자체로 사용하거나 적합한 식품 또는 약품과 혼합하여 사용할 수 있고, 예컨대, 면역 시스템을 자극하거나 전반적인 건강 증진에 치료적으로 유용하다. | ||||||
| 146 | 새로운 젖산균 균주, 이를 함유하는 식용 조성물, 약물 및수의학적 제품 | KR1020047003204 | 2002-12-19 | KR100934747B1 | 2009-12-30 | 데시몬,클라우디오 |
| 2001년 12월 4일자로 DSMZ(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany)에 수탁번호 DSM 14667로 기탁된 스트렙토코커스 써모필러스 ssp. 살리바리우스(
Streptococcus thermophilus ssp. salivarius )의 새로운 균주, 및 이를 함유하는 식용 조성물, 약물 및 수의학적 제품을 개시한다. 상기 균주의 사용은 간 지방증(지방 간) 및 비 알콜성 간 지방증의 예방/치료에 특히 유효하다.
스트렙토코커스 써모필러스 ssp. 살리바리우스, 간 지방증(지방 간), 비 알콜성 간 지방증 |
||||||
| 147 | 사워도우의 제조에서 6 개 이상의 젖산균 및/또는비피더스균 종들의 혼합물 | KR1020077021205 | 2006-03-07 | KR1020070116234A | 2007-12-07 | 데시모네,클라우디오; 피로바노,프랑코 |
| A mixture of at least 6 species of lactic acid bacteria and/or Bifidobacteria is disclosed for use in bakery and medical field. The preferred mixture comprises Streptococcus thermophilus, Bifidobacterium infan-tis, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus. Said mixture is useful for a sourdough, a leavening composition. Baked goods and other food products obtained therefrom are disclosed. These goods have low or no gluten content and are suitable for the integration of the diet of a subject suffering from celiac disease, for decreasing the risk of allergies due to wheat flour al-bumins and globulins, for the treatment of schizophrenic symptoms, in the preparation of products for enteric diet. | ||||||
| 148 | 새로운 젖산균 균주, 이를 함유하는 식용 조성물, 약물 및수의학적 제품 | KR1020047003204 | 2002-12-19 | KR1020040074053A | 2004-08-21 | 데시몬,클라우디오 |
| 2001년 12월 4일자로 DSMZ(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany)에 수탁번호 DSM 14667로 기탁된 스트렙토코커스 써모필러스 ssp. 살리바리우스( Streptococcus thermophilus ssp. salivarius )의 새로운 균주, 및 이를 함유하는 식용 조성물, 약물 및 수의학적 제품을 개시한다. 상기 균주의 사용은 간 지방증(지방 간) 및 비 알콜성 간 지방증의 예방/치료에 특히 유효하다. | ||||||
| 149 | 비열처리 생식품의 제조방법 및 그로부터 수득되는 생식품 | KR1020010081351 | 2001-12-19 | KR1020030050824A | 2003-06-25 | 배희경; 황윤희; 이진희; 임재각 |
| PURPOSE: Provided is a manufacturing method of raw food products and uncooked food manufactured thereby. Therefore, the raw food product has extended storage and improved mouth feeling. CONSTITUTION: A manufacturing method of raw food products is characterized by comprising the steps of: pre-treating grain, fruits or vegetables; and mixing the pre-treated foods with a solution containing live lactic acid bacteria at 15-35 deg.c for 15 minutes to 8 hours. | ||||||
| 150 | MIXTURE OF AT LEAST 6 SPECIES OF LACTIC ACID BACTERIA AND/OR BIFIDOBACTERIA IN THE MANUFACTURE OF SOURDOUGH | PCT/EP2006060505 | 2006-03-07 | WO2006097415A8 | 2007-09-13 | DE SIMONE CLAUDIO; PIROVANO FRANCO |
| A mixture of at least 6 species of lactic acid bacteria and/or Bifidobacteria is disclosed for use in bakery and medical field. The preferred mixture comprises Streptococcus thermophilus, Bifidobacterium infan- tis, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus. Said mixture is useful for a sourdough, a leavening composition. Baked goods and other food products obtained therefrom are disclosed. These goods have low or no gluten content and are suitable for the integration of the diet of a subject suffering from celiac disease, for decreasing the risk of allergies due to wheat flour al- bumins and globulins, for the treatment of schizophrenic symptoms, in the preparation of products for enteric diet. | ||||||
| 151 | COMBINATION OF PROBIOTICS | PCT/FI0200035 | 2002-01-17 | WO02060276A8 | 2003-10-30 | MAEYRAE-MAEKINEN ANNIKA; SUOMALAINEN TARJA; VAARALA OUTI |
| The invention relates to a probiotic combination comprising different combinations of lactobacilli, propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement. | ||||||
| 152 | ACTIVATED BIFIDOBACTERIA AND METHODS OF USE THEREOF | EP15853612 | 2015-10-23 | EP3209308A4 | 2018-06-27 | KYLE DAVID; MILLS DAVID; FREEMAN-SHARKEY SAMARA |
| Some embodiments of the invention include a composition and method for treating dysbiosis in infants. The composition may include a mixture of activated bifidobacteria and a complex oligosaccharide wherein the complex oligosaccharide may be derived from a human or non-human source. | ||||||
| 153 | MIXTURE OF AT LEAST 8 SPECIES OF LACTIC ACID BACTERIA AND/OR BIFIDOBACTERIA IN THE MANUFACTURE OF SOURDOUGH | EP06724958.1 | 2006-03-07 | EP1858336B1 | 2017-11-08 | DE SIMONE, Claudio; PIROVANO, Franco |
| A mixture of at least 6 species of lactic acid bacteria and/or Bifidobacteria is disclosed for use in bakery and medical field. The preferred mixture comprises Streptococcus thermophilus, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus. Said mixture is useful for a sourdough, a leavening composition. Baked goods and other food products obtained therefrom are disclosed. These goods have low or no gluten content and are suitable for the integration of the diet of a subject suffering from celiac disease, for decreasing the risk of allergies due to wheat flour albumins and globulins, for the treatment of schizophrenic symptoms, in the preparation of products for enteric diet. | ||||||
| 154 | Method for stimulating intestinal barrier integrity after non-natural birth | EP11178047.4 | 2006-10-06 | EP2407036B1 | 2015-11-04 | Schmitt, Joachim; Boehm, Günther; Beermann, Christopher |
| The present invention relates to methods for feeding and to compositions to be adminis | ||||||
| 155 | BIFIDOBACTERIUM PROLIFERATION PROMOTER | EP12858857 | 2012-08-24 | EP2796542A4 | 2015-06-17 | ODA HIROTSUGU; YAMAUCHI KOJI; SATO TAKUMI; SHIMIZU KANETADA |
| A peptide dimer comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4, wherein the peptide consisting of the amino acid sequence of SEQ ID NO: 1 and the peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4 are bound through a disulfide bond between a cysteine residue of each peptide is used as an active ingredient of an agent for promoting proliferation of one or more bacterium selected from the group consisting of Bifidobacterium infantis and Bifidobacterium breve. | ||||||
| 156 | Method for stimulating intestinal barrier integrity after birth by caesarean section | EP09161674.8 | 2006-10-06 | EP2105055B1 | 2014-01-22 | Schmitt, Joachim; Boehm, Günther; Beermann, Christopher |
| The present invention relates to methods for feeding and to compositions to be adminis | ||||||
| 157 | Method for stimulating the intestinal flora | EP13171226.7 | 2006-10-20 | EP2638812A1 | 2013-09-18 | Boehm, Günther; Knol, Jan; Stahl, Bernd |
The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c)at least two different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants. |
||||||
| 158 | COMPOSITION FOR PREVENTING OR TREATING ARTHRITIS COMPRISING LACTIC ACID BACTERIA AND COLLANGEN AS ACTIVE INGREDIENTS | EP06798857.6 | 2006-09-22 | EP1945234B1 | 2012-12-19 | IM, Sin Hyeog Department of Life Science; SO, Jae Seon Department of Life Science; YI, Hwa Joong Department of Life Science |
| The present invention relates to a composition for preventing or treating arthritis, which comprises a lactic acid bacterium and collagen as major active ingredients. The present composition shows excellent prevention or treatment efficacies on arthritis of animal models. In addition, since the active ingredients used in the composition of this invention have been recognized to be safe to human, the present composition has considerable safety with enhanced immunomodulatory effect in patients with arthritis. | ||||||
| 159 | NEW STRAINS OF BIFIDOBACTERIUM HAVING THE ABILITY TO PRODUCE GLUTAMINE | EP04705562.9 | 2004-01-27 | EP1587913B1 | 2011-01-19 | MOLIN, Göran; AHRN , Siv; JEPPSSON, Bengt |
| Strains of Bifidobacterium having the ability to survive in the intestinal tract and to produce glutamine in vivo, is new. Independent claims are included for the following: (1) one or more of (I) belonging to the species Bifidobacterium infantis for use in therapy; (2) a composition (II) comprising one or more of (I), in combination with a carrier; and (3) use of one or more of (I), for the preparation of a medicament for treatment of intensive care patients with multiple organ dysfunction and intestinal failure, for prophylaxis in chemotherapy patients and patients with inflammatory diseases, or for postoperative administration after major surgery. ACTIVITY : Gastrointestinal-Gen; Hepatoprotective; Antiinflammatory. MECHANISM OF ACTION : Producer of glutamine and arginine in vivo. Effects of Bifidobacterium strains on dextran sodium sulfate (DDS) induced colitis in rat was tested. Sprague dawley rates were administered orally with different strains of Bifidobacterium for 7 days prior to the induction of colitis (day 0) and were continuously administered for 7 days in combination with DDS (5% w/v dissolved in water). The degree of colitis were determined daily with disease activity index (DAI). Sampling was performed on day 14 and bacterial translocation and quantity in the intestine was determined. DAI was significantly lower in the group receiving B.infantis CURE 19 compared to the groups receiving Lactobacillus paracasei 8700:2 and L.gasseri LG1. After 6 and 7 days, orally administered bacterial strains were able to exercise positive effects by decreasing translocation on experimental colitis in rats. CURE 19 was more effective in counteracting the colitis than the others. | ||||||
| 160 | Method for stimulating the intestinal flora in infants delivered by caesarean section | EP09011197.2 | 2006-10-20 | EP2140771A1 | 2010-01-06 | Boehm, Günther; Stahl, Bernd; Knol, Jan |
The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c)at least two different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants. |
||||||
QQ群二维码
意见反馈
意见反馈